Home › Prostate Cancer › NCT07377006

Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer

Efforts to Enhance Germline Genetic Testing at Lyndon B. Johnson Hospital

Who can join

Ages 18 and older · Men

Inclusion Criteria:

* Diagnosed prostate cancer patients receiving care at Lyndon B. Johnson (LBJ) Hospital
* Were recommended for germline genetic testing by their oncology provider
* Can provide informed consent
* Can communicate in English or Spanish

Exclusion Criteria:

* Prostate cancer patients receiving care at LBJ who are unable to participate due to a serious psychological or cognitive condition

About the study

This clinical trial identifies factors associated with completing genetic testing, aids in the development of a decision support tool, and tests how well the decision support tool works to enhance germline genetic testing in patients with prostate cancer. Germline genetic testing is a guideline-recommended standard of care for many patients with prostate cancer. Completing genetic testing can enable the use of targeted therapies, offers access to novel clinical trials, provides valuable information, and can help identify at risk family members. The decision support tool may educate patients and assist in the decision to engage with germline genetic testing.

What is being tested

• Behavioral Intervention (behavioral)
• Biospecimen Collection (procedure)
• Electronic Health Record Review (other)
• Genetic Counseling (other)
• Genetic Testing (other)
• Interview (other)

Sponsor: M.D. Anderson Cancer Center · Participants: 108 · Started: Feb 2, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07377006

Locations in the U.S.

Conditions

• Prostate Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.